BioMS is running a Phase II/III trial of MBP8298 (a form of myelin-basic protein) to treat progressive MS. The company spent $5.3 million net in the first 6 months of 2005. Clinical trials are a race for money, time, and clinical trial results.

BioMS Medical announces second quarter 2005 results

TSX: MS

EDMONTON, Aug. 12 /CNW/ - BioMS Medical Corp (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced results
for the second quarter ended June 30, 2005.
"Patient enrollment continues as planned for our pivotal Phase II/III
clinical trial evaluating MBP8298 for the treatment of secondary progressive
multiple sclerosis," said Mr. Kevin Giese, President of BioMS Medical. "During
the quarter, we successfully expanded our trial into Europe, appointing
Dr. Carolyn Young as lead investigator in the U.K. and enrolling the first
U.K. patient subsequent to the end of the quarter. Our primary objectives for
the coming months are to ensure enrolment momentum is maintained and to
further expand our trial into additional jurisdictions in Europe."
The consolidated net loss for the second quarter ended June 30, 2005 was
$2.9 million or ($0.05) per share compared with a consolidated net loss of
$2.1 million or ($0.04) per share for the second quarter of the previous year.
For the first six months of 2005, the consolidated net loss was $5.3 million
or ($0.09) per share compared with a consolidated net loss of $6.6 million or
($0.13) per share for the corresponding period in 2004.